

Alert	In conditions with low systemic vascular resistance (SVR) (e.g., septic shock) dobutamine is not the appropriate first drug of choice												
Indication	Inotrope to increase cardiac output in neonates with myocardial dysfunction and unchanged or increased systemic vascular resistance.												
Action	Catecholamine with beta-1 and beta-2 receptor actions which increases myocardial contractility, heart rate and conduction velocity and decreases SVR ¹ . Dose dependent effects: <ul style="list-style-type: none"> • Low dose, 2.5 microgram/kg/min – no significant hemodynamic effects in neonates with cardiovascular compromise • Moderate dose, 5–7.5 microgram/kg/min – increases cardiac output • Higher dose, 5–20 microgram/kg/min – increases cardiac output and blood pressure in hypotensive preterm infants An additional effect of dobutamine on increasing cardiac output has been demonstrated in hypotensive preterm infants receiving dopamine.												
Drug type	Inotropic agent												
Trade name	Abbott Dobutamine Hydrochloride, Dobutamine Sandoz, Dobutamine Hydrochloride DBL, Dobutrex												
Presentation	250 mg/20 mL injection												
Dose	5–20 microgram/kg/minute												
Dose adjustment													
Maximum dose	Use of up to 20 microgram/kg/min reported in neonates												
Total cumulative dose													
Route	Continuous IV infusion												
Preparation	<p>SINGLE STRENGTH continuous IV infusion</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Infusion strength</th> <th style="width: 50%;">Prescribed amount</th> </tr> </thead> <tbody> <tr> <td>1 mL/hour = 10 microgram/kg/minute</td> <td>30 mg/kg dobutamine and make up to 50 mL</td> </tr> </tbody> </table> <p>Draw up 2.4 mL/kg (30 mg/kg of dobutamine) and add glucose 5% or sodium chloride 0.9% to make a final volume of 50 mL. Infusing at a rate of 1 mL/hour = 10 microgram/kg/minute.</p> <p>DOUBLE STRENGTH continuous IV infusion</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Infusion strength</th> <th style="width: 50%;">Prescribed amount</th> </tr> </thead> <tbody> <tr> <td>1 mL/hour = 20 microgram/kg/minute</td> <td>60 mg/kg dobutamine and make up to 50 mL</td> </tr> </tbody> </table> <p>Draw up 4.8 mL/kg (60 mg/kg of dobutamine) and add glucose 5% or sodium chloride 0.9% to make a final volume of 50 mL. Infusing at a rate of 1 mL/hour = 20 microgram/kg/minute.</p> <p>QUADRUPLE STRENGTH continuous IV infusion</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Infusion strength</th> <th style="width: 50%;">Prescribed amount</th> </tr> </thead> <tbody> <tr> <td>1 mL/hour = 40 microgram/kg/minute</td> <td>120 mg/kg dobutamine and make up to 50 mL</td> </tr> </tbody> </table> <p>Draw up 9.6 mL/kg (120 mg/kg of dobutamine) and add glucose 5% or sodium chloride 0.9% to make a final volume of 50 mL. Infusing at a rate of 1 mL/hour = 40 microgram/kg/minute.</p>	Infusion strength	Prescribed amount	1 mL/hour = 10 microgram/kg/minute	30 mg/kg dobutamine and make up to 50 mL	Infusion strength	Prescribed amount	1 mL/hour = 20 microgram/kg/minute	60 mg/kg dobutamine and make up to 50 mL	Infusion strength	Prescribed amount	1 mL/hour = 40 microgram/kg/minute	120 mg/kg dobutamine and make up to 50 mL
Infusion strength	Prescribed amount												
1 mL/hour = 10 microgram/kg/minute	30 mg/kg dobutamine and make up to 50 mL												
Infusion strength	Prescribed amount												
1 mL/hour = 20 microgram/kg/minute	60 mg/kg dobutamine and make up to 50 mL												
Infusion strength	Prescribed amount												
1 mL/hour = 40 microgram/kg/minute	120 mg/kg dobutamine and make up to 50 mL												
Administration	Continuous IV infusion preferably via a central line. Do not flush line or suddenly stop infusion. If Dobutrex brand is used reconstitute each vial with 20 mL WFI to make a concentration of 250 mg/20 mL.												
Monitoring	Continuous heart rate, ECG and blood pressure monitoring preferable. Assess urine output and peripheral perfusion frequently.												
Contraindications	Contraindicated in patients with idiopathic hypertrophic sub aortic stenosis and previous hypersensitivity to dobutamine.												
Precautions	May cause hypotension therefore ensure adequate circulating blood volume prior to commencement.												
Drug interactions	No evidence of drug interactions demonstrated in clinical studies. Exert caution when co-administering with drugs which can cause hypertension or tachycardia.												
Adverse reactions	The positive inotropic and chronotropic effects of dobutamine may cause hypertension, tachyarrhythmias, myocardial ischaemia and ventricular fibrillation. Hypotension may result from vasodilation. May cause hypokalaemia. Phlebitis has been reported.												

Compatibility	<p>Fluids: Glucose 5%, glucose 10%, glucose in sodium chloride solutions, glucose 5% in Hartmann's, Hartmann's, sodium chloride 0.9%, sodium chloride 0.45%</p> <p>Y site: Amino acid solutions, adrenaline hydrochloride, amifostine, amiodarone, anidulafungin, atracurium, aztreonam, bivalirudin (dobutamine concentrations up to 4 mg/mL), caspofungin, ciprofloxacin, cisatracurium, dexmedetomidine, dopamine, eptifibatid, fluconazole, glyceryl trinitrate, granisetron, haloperidol lactate, labetalol, linezolid, milrinone, noradrenaline, pancuronium, pethidine, ranitidine, remifentanyl, streptokinase, tigecycline, tirofiban, vecuronium, zidovudine.</p>
Incompatibility	<p>Fluids: Sodium bicarbonate, alkaline solutions, diluents that contain sodium bisulfite and ethanol.</p> <p>Y site: Aciclovir, alteplase, aminophylline, ampicillin, azathioprine, benzylpenicillin, calcium gluconate, cefotaxime, ceftazidime, ceftriaxone, cephazolin, chloramphenicol, dexamethasone, ertapenem, esomeprazole, flucloxacillin, folic acid, fosfarnet, ganciclovir, heparin sodium, hydrocortisone sodium succinate, indomethacin, ketorolac, phenobarbitone, piperacillin-tazobactam (EDTA-free), potassium chloride, sodium bicarbonate, thiopentone, ticarcillin-clavulanate.</p>
Stability	<p>Reconstituted solution – Dobutrex brand only: Stable for 6 hours at 25°C and 24 hours at 2 to 8°C.</p> <p>Diluted solution – other brands: Stable for 24 hours at 25°C.</p> <p>Solutions may turn pink and colour will increase with time but with no significant loss of potency. Discard solutions that are hazy or contain particles.</p>
Storage	<p>Vial: Store below 25°C. Protect from light. Discard remaining solution after use.</p>
Excipients	
Special comments	Dobutamine should always have a dedicated line to prevent accidental bolus.
Evidence	<p>Efficacy:</p> <p>Treatment of hypotension in preterm infants: Dobutamine is less effective than dopamine at increasing blood pressure in hypotensive infants but this may not change the clinical outcome. A single study² reported left ventricular output increased with dobutamine compared to a decrease with dopamine (LOE I, GOR C)³.</p> <p>Treatment of low systemic blood flow: Dobutamine increased superior vena cava (SVC) flow with little change in blood pressure, whereas dopamine increased blood pressure with little change in SVC flow. There was no difference in clinical outcome (LOE II, GOR C)⁴⁻⁶.</p> <p>Summary:</p> <p>Dobutamine is recommended to increase cardiac output in neonates with myocardial dysfunction and unchanged or increased systemic vascular resistance (SVR). In conditions with low SVR (e.g., septic shock) dobutamine is not the appropriate first drug of choice¹.</p> <p>Safety:</p> <p>No evidence of an effect on the incidence of adverse neuroradiological sequelae (severe periventricular haemorrhage and/or periventricular leucomalacia), or on the incidence of tachycardia. Insufficient data confirming long term benefit and safety of dobutamine³. Common side effects reported were ventricular arrhythmias, tachycardia, hypotension and chest pain (children) (LOE III-2, GOR B)⁷.</p> <p>Pharmacokinetics:</p> <p>Dobutamine concentrations positively correlated with infusion dosages. Range of values vary widely between patients despite similar doses⁷. Short half-life around 2 minutes⁸.</p>
Practice points	
References	<ol style="list-style-type: none"> Noori, S. and I. Seri, Neonatal blood pressure support: the use of inotropes, lusitropes, and other vasopressor agents. Clin Perinatol, 2012. 39(1): p. 221–38. Roze, J.C., et al., Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child, 1993. 69(1 Spec No): p. 59–63. Subhedar, N.V. and N.J. Shaw, Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database Syst Rev, 2003(3): p. CD001242. Osborn, D., N. Evans, and M. Kluckow, Randomized trial of dobutamine versus dopamine in preterm

	<p>infants with low systemic blood flow. <i>J Pediatr</i>, 2002. 140(2): p. 183–91.</p> <p>5. Osborn, D.A., N. Evans, and M. Kluckow, Left ventricular contractility in extremely premature infants in the first day and response to inotropes. <i>Pediatr Res</i>, 2007. 61(3): p. 335–40.</p> <p>6. Osborn, D.A., et al., Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. <i>Pediatrics</i>, 2007. 120(2): p. 372–80.</p> <p>7. Mahoney, L., et al., A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates. <i>Pediatr Cardiol</i>, 2015 Sep 7. [Epub ahead of print].</p> <p>8. Schwartz, P.H., M.K. Eldadah, and C.J. Newth, The pharmacokinetics of dobutamine in pediatric intensive care unit patients. <i>Drug Metab Dispos</i>, 1991. 19(3): p. 614–9.</p> <p>9. MIMSONline Accessed via CIAP on 21/10/15.</p> <p>10. Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.acs.hcn.com.au. Accessed via CIAP on 21/10/15.</p> <p>11. Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014.</p> <p>12. Neofax accessed on www.neofax.micromedex.solutions.com on 29/9/15.</p>
--	--

VERSION/NUMBER	DATE
Original 1	9/11/2015
Revised	5/01/2021
REVIEW	5/01/2026

Authors Contribution

Original author/s	David Osborn, Srinivas Bolisetty
Evidence Review	David Osborn
Expert review	
Nursing Review	Eszter Jozsa, Kirsty Minter
Pharmacy Review	Mariella De Rosa, Wendy Huynh
ANMF Group contributors	Ansar Kunjunju, Chris Wake, Nilkant Phad, Himanshu Popat, Bhavesh Mehta, John Sinn, Carmen Burman, Jessica Mehegan, Thao Tran, Michelle Jenkins, Helen Huynh
Final editing and review of the original	Ian Whyte
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty